Skip to main content

Letter

Letter to FDA on Lagging Approvals for Complex Generic Drugs


01.17.20

Excerpt: “We are interested in identifying ways to help reduce the costs of health care for patients, including the costs of prescription drugs. Generic versions of brand-name drugs provide substantial cost savings for patients and third-party payers and account for nine out of ten prescriptions filled in the U.S.,” the bipartisan Committee members wrote to FDA.

CLICK HERE to read the letter to FDA.

Letter